BioNebicine Corporation, a privately held biotech company, is pleased to announce that it has retained Environmental Diagnostics Laboratory, a division of PureAirTM Control Services, Inc., to conduct numerous controlled examinations of particle size emitted by an ultrasonic vibrating mesh nebulizer design with various medical formulations for BioNebicine.
Pulmonary delivery of various medicinal and non-medicinal formulations requires delivery of the formulation such that the particulate size is accepted by the lungs’ alveolus. The Company, in conjunction with its partners, has developed a patent-pending nebulizer device and the necessary solutions and formulations required to achieve the targeted particle size for maximum absorption within the pulmonary system.
BioNebicine has and will be focused on the delivery of pharmaceutical medical formulations in the pharmaceutical market. The Company may also explore various recreation uses such as caffeine and alcohol, as well as delivery of various supplements such as vitamins and weight loss formulations.
Donald M. Pell MD. CEO and President
Dr. Govindan Nair, Vice President and Board Member
Mr. Paul Messina, Interim Chief Financial Officer